Shanghai United Imaging Healthcare (688271) H1 2024 earnings summary

Executive summary

• Achieved revenue of RMB 5.33 billion for H1 2024, up 1.18% year-over-year; net profit attributable to shareholders was RMB 950 million, up 1.33% year-over-year.

• Maintained leading market positions in CT, MR, MI, and XR product lines in China; international revenue grew 30% year-over-year, now 17.5% of total.

• R&D investment reached RMB 1.02 billion, 19.07% of revenue, with 360 new IP applications and 379 new IP grants.

• Proposed cash dividend of RMB 1.20 per 10 shares, totaling RMB 98.27 million, representing 10.34% of H1 net profit.

• No major litigation, regulatory, or compliance issues reported during the period.

Financial highlights

• Revenue: RMB 5.33 billion, up 1.18% year-over-year.

• Net profit attributable to shareholders: RMB 950 million, up 1.33% year-over-year.

• Gross margin: 50.37%, up 1.66 percentage points year-over-year.

• Basic and diluted EPS: RMB 1.16, up 1.75% year-over-year.

• Net cash from operating activities: RMB 798 million, compared to outflow of RMB 625 million in H1 2023.

• R&D expenses: RMB 1.02 billion, 19.07% of revenue, up 1.7 percentage points year-over-year.

• Total assets: RMB 26.70 billion; net assets: RMB 19.59 billion.

Outlook and guidance

• Company will continue to expand international markets, strengthen R&D, and accelerate commercialization of new products.

• Expects to benefit from government policies supporting medical equipment upgrades and healthcare infrastructure.

• Will maintain high R&D investment and focus on high-end and innovative medical imaging and therapy solutions.